Published in Mol Microbiol on February 01, 2001
Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res (2011) 2.21
Determinants for the development of visceral leishmaniasis disease. PLoS Pathog (2013) 1.22
Transmembrane molecules for phylogenetic analyses of pathogenic protists: Leishmania-specific informative sites in hydrophilic loops of trans- endoplasmic reticulum N-acetylglucosamine-1-phosphate transferase. Eukaryot Cell (2006) 1.19
The amastigote forms of Leishmania are experts at exploiting host cell processes to establish infection and persist. Int J Parasitol (2007) 1.17
Leishmania priming of human dendritic cells for CD40 ligand-induced interleukin-12p70 secretion is strain and species dependent. Infect Immun (2002) 1.08
Genome-wide SNP and microsatellite variation illuminate population-level epidemiology in the Leishmania donovani species complex. Infect Genet Evol (2011) 0.98
Characterization of a Leishmania stage-specific mitochondrial membrane protein that enhances the activity of cytochrome c oxidase and its role in virulence. Mol Microbiol (2010) 0.96
Temperature increase prevails over acidification in gene expression modulation of amastigote differentiation in Leishmania infantum. BMC Genomics (2010) 0.95
Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice. J Immunol (2013) 0.92
Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites. J Trop Med (2011) 0.91
Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis. PLoS Negl Trop Dis (2013) 0.89
Genetically modified organisms and visceral leishmaniasis. Front Immunol (2014) 0.88
Transgenic Leishmania and the immune response to infection. Parasite Immunol (2008) 0.88
A genomic-based approach combining in vivo selection in mice to identify a novel virulence gene in Leishmania. PLoS Negl Trop Dis (2008) 0.86
A genomic scale map of genetic diversity in Trypanosoma cruzi. BMC Genomics (2012) 0.84
Genetic analysis of Leishmania donovani tropism using a naturally attenuated cutaneous strain. PLoS Pathog (2014) 0.84
Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures. MBio (2016) 0.82
Biomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis - discovery and implications. Front Immunol (2014) 0.82
Comparative in-silico genome analysis of Leishmania (Leishmania) donovani: A step towards its species specificity. Meta Gene (2014) 0.82
A2 gene of Old World cutaneous Leishmania is a single highly conserved functional gene. BMC Infect Dis (2005) 0.81
Effect of A2 gene on infectivity of the nonpathogenic parasite Leishmania tarentolae. Parasitol Res (2011) 0.81
Comparative Life Cycle Transcriptomics Revises Leishmania mexicana Genome Annotation and Links a Chromosome Duplication with Parasitism of Vertebrates. PLoS Pathog (2015) 0.81
Cutaneous Infection with Leishmania major Mediates Heterologous Protection against Visceral Infection with Leishmania infantum. J Immunol (2015) 0.80
Leishmania tarentolae molecular signatures in a 300 hundred-years-old human Brazilian mummy. Parasit Vectors (2015) 0.79
Role of cytosolic glyceraldehyde-3-phosphate dehydrogenase in visceral organ infection by Leishmania donovani. Eukaryot Cell (2012) 0.78
Mitigating an undesirable immune response of inherent susceptibility to cutaneous leishmaniosis in a mouse model: the role of the pathoantigenic HISA70 DNA vaccine. Vet Res (2012) 0.77
Genetically Engineered Ascorbic acid-deficient Live Mutants of Leishmania donovani induce long lasting Protective Immunity against Visceral Leishmaniasis. Sci Rep (2015) 0.77
Molecular Analysis of A2-genes Encoding Stage-specific S Antigen-like Proteins among Isolates from Iranian Cutaneous and Visceral Leishmaniasis. Iran J Basic Med Sci (2011) 0.76
HisAK70: progress towards a vaccine against different forms of leishmaniosis. Parasit Vectors (2015) 0.76
Optimized CRISPR-Cas9 Genome Editing for Leishmania and Its Use To Target a Multigene Family, Induce Chromosomal Translocation, and Study DNA Break Repair Mechanisms. mSphere (2017) 0.75
Identification of internalin-A-like virulent proteins in Leishmania donovani. Parasit Vectors (2016) 0.75
Postgenomic research on leishmaniasis: a critical self-appraisal. Trends Parasitol (2008) 0.75
The Leishmania metaphylome: a comprehensive survey of Leishmania protein phylogenetic relationships. BMC Genomics (2015) 0.75
Application of Recombinant Proteins for Serodiagnosis of Visceral Leishmaniasis in Humans and Dogs. Iran Biomed J (2016) 0.75
Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature (1998) 6.16
Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem (1986) 4.80
Human papillomavirus type 16 DNA cooperates with activated ras in transforming primary cells. EMBO J (1987) 3.81
Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol (1999) 3.35
Loss of virulence in Leishmania donovani deficient in an amastigote-specific protein, A2. Proc Natl Acad Sci U S A (1997) 2.53
Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. EMBO J (1984) 2.45
Intracellular infection by Leishmania donovani inhibits macrophage apoptosis. J Immunol (1994) 2.12
Analysis of human p53 proteins and mRNA levels in normal and transformed cells. Eur J Biochem (1986) 1.91
Identification of human papillomavirus type 18 E6 polypeptide in cells derived from human cervical carcinomas. J Gen Virol (1987) 1.78
The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. Oncogene (1992) 1.68
Developmental gene expression in Leishmania donovani: differential cloning and analysis of an amastigote-stage-specific gene. Mol Cell Biol (1994) 1.57
Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis (2001) 1.53
Identification and overexpression of the A2 amastigote-specific protein in Leishmania donovani. Mol Biochem Parasitol (1996) 1.52
The developmental expression of Leishmania donovani A2 amastigote-specific genes is post-transcriptionally mediated and involves elements located in the 3'-untranslated region. J Biol Chem (1996) 1.51
Analysis of the anti-p53 antibody response in cancer patients. Cancer Res (1993) 1.49
Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. Ludwig-McGill Study Group. Rev Panam Salud Publica (1999) 1.46
Leishmania donovani lipophosphoglycan selectively inhibits signal transduction in macrophages. J Immunol (1991) 1.46
Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine (2001) 1.37
Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin Infect Dis (2005) 1.32
Inhibition of macrophage protein kinase C-mediated protein phosphorylation by Leishmania donovani lipophosphoglycan. J Immunol (1992) 1.32
The human papillomavirus type 16 E5 gene cooperates with the E7 gene to stimulate proliferation of primary cells and increases viral gene expression. Virology (1994) 1.27
General suppression of macrophage gene expression during Leishmania donovani infection. J Immunol (2001) 1.25
c-fos and tumor necrosis factor gene expression in Leishmania donovani-infected macrophages. Mol Cell Biol (1989) 1.19
Antibody response against a Leishmania donovani amastigote-stage-specific protein in patients with visceral leishmaniasis. Clin Diagn Lab Immunol (1997) 1.17
Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J Infect Dis (1999) 1.15
The expression of biologically active human p53 in Leishmania cells: a novel eukaryotic system to produce recombinant proteins. Nucleic Acids Res (1995) 1.15
Effect of human papillomavirus type 16 oncogenes on MAP kinase activity. J Virol (1995) 1.08
DNA damage induced p53 mediated transcription is inhibited by human papillomavirus type 18 E6. Oncogene (1994) 1.07
Alteration of Leishmania donovani infection levels by selective impairment of macrophage signal transduction. J Immunol (1993) 1.04
Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation. Oncogene (1996) 1.01
Expression of human papillomavirus type 6 and type 16 capsid proteins in bacteria and their antigenic characterization. J Gen Virol (1987) 0.97
P53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. Int J Cancer (2000) 0.94
Regulation of tumor necrosis factor gene expression and protein synthesis in murine macrophages treated with recombinant tumor necrosis factor. J Immunol (1990) 0.93
Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response. Vaccine (2001) 0.92
Control of interferon signaling in human papillomavirus infection. Cytokine Growth Factor Rev (2001) 0.91
Analysis of antisense and double stranded RNA downregulation of A2 protein expression in Leishmania donovani. Mol Biochem Parasitol (2000) 0.89
Molecular analysis of different allelic variants of wild-type human p53. Biochem Cell Biol (1993) 0.88
A2rel: a constitutively expressed Leishmania gene linked to an amastigote-stage-specific gene. Mol Biochem Parasitol (1998) 0.87
The expression of human papillomavirus type 18 E6 protein in bacteria and the production of anti-E6 antibodies. J Gen Virol (1986) 0.85
Inducible expression of suicide genes in Leishmania donovani amastigotes. J Biol Chem (1998) 0.83
Identification of genes induced by a macrophage activator, S-28463, using gene expression array analysis. Antimicrob Agents Chemother (2001) 0.83
Development of a p53 responsive GFP reporter; identification of live cells with p53 activity. J Biotechnol (2001) 0.81
Expression of the human papillomavirus E7 oncogene during cell transformation is sufficient to induce susceptibility to lysis by activated macrophages. J Immunol (1991) 0.78
Leishmania donovani infection enhances macrophage viability in the absence of exogenous growth factor. J Leukoc Biol (1994) 0.78
Characterization of a beta-tubulin gene and a beta-tubulin gene products of Brugia pahangi. Mol Biochem Parasitol (1991) 0.78
Identification of a novel Brugia pahangi beta-tubulin gene (beta 2) and a 22-nucleotide spliced leader sequence on beta 1-tubulin mRNA. Mol Biochem Parasitol (1992) 0.77
Clearance of infection with Mycobacterium bovis BCG in mice is enhanced by treatment with S28463 (R-848), and its efficiency depends on expression of wild-type Nramp1 (resistance allele). Antimicrob Agents Chemother (2001) 0.75
The use of monoclonal antibodies for selection of a low-abundance mRNA: p53. Biochem Soc Trans (1984) 0.75